CATH Search:   
       by CATH code, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Class: Mainly Beta (13760)
(-)
Architecture: Beta Barrel (4804)
(-)
Topology: Thrombin, subunit H (1535)
(-)
Homologous Superfamily: Trypsin-like serine proteases (1488)
(-)
Cattle (Bos taurus) (308)
1A0HB:333-437,B:565-579; E:333-437,E:565-579; B:321-332,B:438-564; E:321-332,E:438-564THE X-RAY CRYSTAL STRUCTURE OF PPACK-MEIZOTHROMBIN DESF1: KRINGLE/THROMBIN AND CARBOHYDRATE/KRINGLE/THROMBIN INTERACTIONS AND LOCATION OF THE LINKER CHAIN
1AB9C:150-245; B:16-146CRYSTAL STRUCTURE OF BOVINE GAMMA-CHYMOTRYPSIN
1AFQC:150-245; B:16-146CRYSTAL STRUCTURE OF BOVINE GAMMA-CHYMOTRYPSIN COMPLEXED WITH A SYNTHETIC INHIBITOR
1AQ7A:16-27,A:121-232; A:28-120,A:233-244TRYPSIN WITH INHIBITOR AERUGINOSIN 98-B
1AUJA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN COMPLEXED TO META-CYANO-BENZYLIC INHIBITOR
1AVGH:28-120,H:233-247; H:16-27,H:121-232THROMBIN INHIBITOR FROM TRIATOMA PALLIDIPENNIS
1AZ8A:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN COMPLEXED TO BIS-PHENYLAMIDINE INHIBITOR
1BBRK:28-120,K:233-247; N:28-120,N:233-247; K:16-27,K:121-232; N:16-27,N:121-232; E:149B-247; H:16-149ATHE STRUCTURE OF RESIDUES 7-16 OF THE A ALPHA CHAIN OF HUMAN FIBRINOGEN BOUND TO BOVINE THROMBIN AT 2.3 ANGSTROMS RESOLUTION
1BJUA:16-27,A:121-232; A:28-120,A:233-245BETA-TRYPSIN COMPLEXED WITH ACPU
1BJVA:16-27,A:121-232; A:28-120,A:233-245BETA-TRYPSIN COMPLEXED WITH APPU
1BTHH:28-120,H:233-242; K:28-120,K:233-242; H:16-27,H:121-232; K:16-27,K:121-232STRUCTURE OF THROMBIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
1BTPA:16-27,A:121-232; A:28-120,A:233-245UNIQUE BINDING OF A NOVEL SYNTHETIC INHIBITOR, N-[3-[4-[4-(AMIDINOPHENOXY)-CARBONYL]PHENYL]-2-METHYL-2-PROPENOYL]-N-ALLYLGLYCINE METHANESULFONATE TO BOVINE TRYPSIN, REVEALED BY THE CRYSTAL STRUCTURE OF THE COMPLEX
1BTWA:16-27,A:121-232; A:28-120,A:233-245EPISELECTION: NOVEL KI ~NANOMOLAR INHIBITORS OF SERINE PROTEASES SELECTED BY BINDING OR CHEMISTRY ON AN ENZYME SURFACE
1BTZA:16-27,A:121-232; A:28-120,A:233-245EPISELECTION: NOVEL KI ~NANOMOLAR INHIBITORS OF SERINE PROTEASES SELECTED BY BINDING OR CHEMISTRY ON AN ENZYME SURFACE
1C1NA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1OA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1PA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1QA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1RA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1SA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1TA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2DA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2EA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2FA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2GA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2HA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2IA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2JA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2KA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2LA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2MA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C5PA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5QA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5RA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5SA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5TA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5UA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5VA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C9TA:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; E:16-27,E:121-232; F:16-27,F:121-232; A:28-120,A:233-245; B:28-120,B:233-245; C:28-120,C:233-245; D:28-120,D:233-245; E:28-120,E:233-245; F:28-120,F:233-245COMPLEX OF BDELLASTASIN WITH BOVINE TRYPSIN
1CA0C:149-245; H:149-245; B:16-146; G:16-146BOVINE CHYMOTRYPSIN COMPLEXED TO APPI
1CBWC:149-245; H:149-245; B:16-146; G:16-146BOVINE CHYMOTRYPSIN COMPLEXED TO BPTI
1CE5A:16-27,A:121-232; A:28-120,A:233-245BOVINE PANCREAS BETA-TRYPSIN IN COMPLEX WITH BENZAMIDINE
1CGIE:28-120,E:233-245; E:16-27,E:121-232THREE-DIMENSIONAL STRUCTURE OF THE COMPLEXES BETWEEN BOVINE CHYMOTRYPSINOGEN*A AND TWO RECOMBINANT VARIANTS OF HUMAN PANCREATIC SECRETORY TRYPSIN INHIBITOR (KAZAL-TYPE)
1CGJE:28-120,E:233-245; E:16-27,E:121-232THREE-DIMENSIONAL STRUCTURE OF THE COMPLEXES BETWEEN BOVINE CHYMOTRYPSINOGEN*A AND TWO RECOMBINANT VARIANTS OF HUMAN PANCREATIC SECRETORY TRYPSIN INHIBITOR (KAZAL-TYPE)
1CHGA:28-120,A:233-242; A:16-27,A:121-232CHYMOTRYPSINOGEN,2.5 ANGSTROMS CRYSTAL STRUCTURE, COMPARISON WITH ALPHA-CHYMOTRYPSIN,AND IMPLICATIONS FOR ZYMOGEN ACTIVATION
1CHOG:149-245; F:16-146CRYSTAL AND MOLECULAR STRUCTURES OF THE COMPLEX OF ALPHA-*CHYMOTRYPSIN WITH ITS INHIBITOR TURKEY OVOMUCOID THIRD DOMAIN AT 1.8 ANGSTROMS RESOLUTION
1D6RA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF CANCER CHEMOPREVENTIVE BOWMAN-BIRK INHIBITOR IN TERNARY COMPLEX WITH BOVINE TRYPSIN AT 2.3 A RESOLUTION. STRUCTURAL BASIS OF JANUS-FACED SERINE PROTEASE INHIBITOR SPECIFICITY
1DLKB:28-120,B:233-243; D:28-120,D:233-243; B:16-27,B:121-232; D:16-27,D:121-232CRYSTAL STRUCTURE ANALYSIS OF DELTA-CHYMOTRYPSIN BOUND TO A PEPTIDYL CHLOROMETHYL KETONE INHIBITOR
1EJMA:16-27,A:121-232; C:16-27,C:121-232; E:16-27,E:121-232; A:28-120,A:233-245; C:28-120,C:233-245; E:28-120,E:233-245CRYSTAL STRUCTURE OF THE BPTI ALA16LEU MUTANT IN COMPLEX WITH BOVINE TRYPSIN
1EKBB:16-27,B:121-232; B:28-120,B:233-243THE SERINE PROTEASE DOMAIN OF ENTEROPEPTIDASE BOUND TO INHIBITOR VAL-ASP-ASP-ASP-ASP-LYS-CHLOROMETHANE
1EUFA:16-27,A:121-232; A:28-120,A:233-243BOVINE DUODENASE(NEW SERINE PROTEASE), CRYSTAL STRUCTURE
1EX3A:28-120,A:233-243; A:16-27,A:121-232CRYSTAL STRUCTURE OF BOVINE CHYMOTRYPSINOGEN A (TETRAGONAL)
1F0TA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN COMPLEXED WITH RPR131247
1F0UA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN COMPLEXED WITH RPR128515
1F2SE:16-27,E:121-232; E:28-120,E:233-245CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE BETA-TRYPSIN AND MCTI-A, A TRYPSIN INHIBITOR OF SQUASH FAMILY AT 1.8 A RESOLUTION
1FONA:11-111,A:228-240; B:11-111,B:228-240; A:9-10,A:112-227; B:9-10,B:112-227CRYSTAL STRUCTURE OF BOVINE PROCARBOXYPEPTIDASE A-S6 SUBUNIT III, A HIGHLY STRUCTURED TRUNCATED ZYMOGEN E
1G36A:16-27,A:121-232; A:28-120,A:233-245TRYPSIN INHIBITOR COMPLEX
1G3BA:16-27,A:121-232; A:28-120,A:233-245BOVINE BETA-TRYPSIN BOUND TO META-AMIDINO SCHIFF BASE MAGNESIUM(II) CHELATE
1G3CA:16-27,A:121-232; A:28-120,A:233-245BOVINE BETA-TRYPSIN BOUND TO PARA-AMIDINO SCHIFF BASE IRON(III) CHELATE
1G3DA:16-27,A:121-232; A:28-120,A:233-245BOVINE BETA-TRYPSIN BOUND TO META-AMIDINO SCHIFF BASE COPPER (II) CHELATE
1G3EA:16-27,A:121-232; A:28-120,A:233-245BOVINE BETA-TRYPSIN BOUND TO PARA-AMIDINO SCHIFF-BASE COPPER (II) CHELATE
1G9IE:16-27,E:121-232; E:28-120,E:233-245CRYSTAL STRUCTURE OF BETA-TRYSIN COMPLEX IN CYCLOHEXANE
1GBTA:16-27,A:121-232; A:28-120,A:233-245STRUCTURE OF AN ACYL-ENZYME INTERMEDIATE DURING CATALYSIS: (GUANIDINOBENZOYL) TRYPSIN
1GCDA:28-120,A:233-243; A:16-27,A:121-232REFINED CRYSTAL STRUCTURE OF "AGED" AND "NON-AGED" ORGANOPHOSPHORYL CONJUGATES OF GAMMA-CHYMOTRYPSIN
1GG6C:149-245; B:16-146CRYSTAL STRUCTURE OF GAMMA CHYMOTRYPSIN WITH N-ACETYL-PHENYLALANINE TRIFLUOROMETHYL KETONE BOUND AT THE ACTIVE SITE
1GGDC:151-245; B:16-146CRYSTAL STRUCTURE OF GAMMA CHYMOTRYPSIN WITH N-ACETYL-LEUCIL-PHENYLALANINE ALDEHYDE BOUND AT THE ACTIVE SITE
1GHAG:151-245; F:16-146A SECOND ACTIVE SITE IN CHYMOTRYPSIN? THE X-RAY CRYSTAL STRUCTURE OF N-ACETYL-D-TRYPTOPHAN BOUND TO GAMMA-CHYMOTRYPSIN
1GHZA:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI0A:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI1A:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI2A:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI3A:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI4A:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI5A:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI6A:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GJ6A:16-27,A:121-232; A:28-120,A:233-245ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GMCG:151-245; F:16-146THE X-RAY CRYSTAL STRUCTURE OF THE TETRAHEDRAL INTERMEDIATE OF GAMMA-CHYMOTRYPSIN IN HEXANE
1GMDG:151-245; F:16-146X-RAY CRYSTAL STRUCTURE OF GAMMA-CHYMOTRYPSIN IN HEXANE
1GMHG:150-245; F:16-146REFINED CRYSTAL STRUCTURE OF "AGED" AND "NON-AGED" ORGANOPHOSPHORYL CONJUGATES OF GAMMA-CHYMOTRYPSIN
1HJAC:149-245; B:16-146LYS 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH ALPHA-CHYMOTRYPSIN
1HRTH:28-120,H:233-247; H:16-27,H:121-232THE STRUCTURE OF A COMPLEX OF BOVINE ALPHA-THROMBIN AND RECOMBINANT HIRUDIN AT 2.8 ANGSTROMS RESOLUTION
1ID5H:28-120,H:233-244; H:16-27,H:121-232CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEX WITH PROTEASE INHIBITOR ECOTIN
1J8AA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF BENZAMIDINE INHIBITED BOVINE PANCREATIC TRYPSIN AT 105K TO 1.21A RESOLUTION FROM LABORATORY SOURCE WITH HIGH NUMBER OF WATERS MODELLED
1JIRA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF TRYPSIN COMPLEX WITH AMYLAMINE IN CYCLOHEXANE
1JRSA:16-27,A:121-232; A:28-120,A:233-245HEMIACETAL COMPLEX BETWEEN LEUPEPTIN AND TRYPSIN
1JRTA:16-27,A:121-232; A:28-120,A:233-245HEMIACETAL COMPLEX BETWEEN LEUPEPTIN AND TRYPSIN
1K1IA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1JA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1LA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1MA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1NA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1OA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1PA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN-INHIBITOR COMPLEX
1K2I1:28-120,1:233-243; 1:18-27,1:121-232CRYSTAL STRUCTURE OF GAMMA-CHYMOTRYPSIN IN COMPLEX WITH 7-HYDROXYCOUMARIN
1KIGH:16-27,H:121-232; H:28-120,H:233-246BOVINE FACTOR XA
1LQEA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF TRYPSIN IN COMPLEX WITH 79.
1MAXA:16-27,A:121-232; A:28-120,A:233-245BETA-TRYPSIN PHOSPHONATE INHIBITED
1MAYA:16-27,A:121-232; A:28-120,A:233-245BETA-TRYPSIN PHOSPHONATE INHIBITED
1MKWH:28-120,H:233-243; K:28-120,K:233-243; H:16-27,H:121-232; K:16-27,K:121-232THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA-THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING
1MKXH:28-120,H:233-243; K:28-120,K:233-243; H:16-27,H:121-232; K:16-27,K:121-232THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA-THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING
1MTNC:149-245; G:149-245; B:16-146; F:16-146BOVINE ALPHA-CHYMOTRYPSIN:BPTI CRYSTALLIZATION
1MTSA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1MTUA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1MTVA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1MTWA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1N6XA:16-27,A:121-232; A:28-120,A:233-245RIP-PHASING ON BOVINE TRYPSIN
1N6YA:16-27,A:121-232; A:28-120,A:233-245RIP-PHASING ON BOVINE TRYPSIN
1N8OC:149-245; B:16-146CRYSTAL STRUCTURE OF A COMPLEX BETWEEN BOVINE CHYMOTRYPSIN AND ECOTIN
1NC6A:16-27,A:121-232; A:28-120,A:233-245POTENT, SMALL MOLECULE INHIBITORS OF HUMAN MAST CELL TRYPTASE. ANTI-ASTHMATIC ACTION OF A DIPEPTIDE-BASED TRANSITION STATE ANALOGUE CONTAINING BENZOTHIAZOLE KETONE
1NTPA:16-27,A:121-232; A:28-120,A:233-245USE OF THE NEUTRON DIFFRACTION H/D EXCHANGE TECHNIQUE TO DETERMINE THE CONFORMATIONAL DYNAMICS OF TRYPSIN
1O2HA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2IA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2JA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2KA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2LA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2MA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2NA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2OA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2PA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2QA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2RA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2SA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2TA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2UA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2VA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2WA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2XA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2YA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2ZA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O30A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O31A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O32A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O33A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O34A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O35A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O36A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O37A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O38A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O39A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3AA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3BA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3CA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3DA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3EA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3FA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3GA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3HA:16-27,A:121-232; A:28-120,A:233-244ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3IA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3JA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3KA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3LA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3MA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3NA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3OA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1OX1A:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF THE BOVINE TRYPSIN COMPLEX WITH A SYNTHETIC 11 PEPTIDE INHIBITOR
1OYQA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN INHIBITOR COMPLEX
1P2IA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2JA:16-27,A:121-232; A:28-120,A:233-242STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2KA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2MA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2NA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2OA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2QA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1PPEE:16-27,E:121-232; E:28-120,E:233-245THE REFINED 2.0 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE BETA-TRYPSIN AND CMTI-I, A TRYPSIN INHIBITOR FROM SQUASH SEEDS (CUCURBITA MAXIMA): TOPOLOGICAL SIMILARITY OF THE SQUASH SEED INHIBITORS WITH THE CARBOXYPEPTIDASE A INHIBITOR FROM POTATOES
1PYTC:428-520,C:633-645; D:728-820,D:933-944; C:416-427,C:521-632; D:716-727,D:821-932TERNARY COMPLEX OF PROCARBOXYPEPTIDASE A, PROPROTEINASE E, AND CHYMOTRYPSINOGEN C
1QA0A:7-18,A:109-216; A:19-108,A:217-229BOVINE TRYPSIN 2-AMINOBENZIMIDAZOLE COMPLEX
1QB1A:7-18,A:109-216; A:19-108,A:217-229BOVINE TRYPSIN WITH 1-[2-[5-[AMINO(IMINO)METHYL]-2-HYDROXYPHENOXY]-6-[3-(4,5-DIHYDRO-1-METHYL-1H-IMIDAZOL-2-YL)PHENOXY]PYRIDIN-4-YL]PIPERIDINE-3-CARBOXYLIC ACID (ZK-806974)
1QB6A:7-18,A:109-216; A:19-108,A:217-229BOVINE TRYPSIN 3,3'-[3,5-DIFLUORO-4-METHYL-2, 6-PYRIDINEDIYLBIS(OXY)]BIS(BENZENECARBOXIMIDAMIDE) (ZK-805623) COMPLEX
1QB9A:7-18,A:109-216; A:19-108,A:217-229BOVINE TRYPSIN 7-[[2-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-9H-CARBOZOL-9-YL] METHYL]NAPHTHALENE-2-CARBOXIMIDAMIDE (ZK-806450) COMPLEX
1QBNA:7-18,A:109-216; A:19-108,A:217-229BOVINE TRYPSIN 2-[AMINO(IMINO)METHYL]-2-HYDROXYPHENOXY]-6-[3-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)PHENOXY]PYRIDINE-4-CARBOXYLIC ACID (ZK-806688) COMPLEX
1QBOA:7-18,A:109-216; A:19-108,A:217-229BOVINE TRYPSIN 7-[[6-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-2-METHYL-BENZIMIDAZOL-1-YL]METHYL]NAPHTHALENE-2-CARBOXIMIDAMID ZK-806711 INHIBITOR COMPLEX
1QCPA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF THE RWJ-51084 BOVINE PANCREATIC BETA-TRYPSIN AT 1.8 A
1RXPA:16-27,A:121-232; A:28-120,A:233-245STRUCTURE OF TRYPSIN (ORTHORHOMBIC) WITH 1-(4-TERT-BUTYLCARBAMOYL- PIPERAZINE-1-CARBONYL)-3-(3-GUANIDINO-PROPYL)-4-OXO-AZETIDINE-2-CARBOXYLIC ACID
1S0QA:660-671,A:762-869; A:672-761,A:870-881NATIVE BOVINE PANCREATIC TRYPSIN
1S0RA:1-12,A:103-210; A:13-102,A:211-222BOVINE PANCREATIC TRYPSIN INHIBITED WITH BENZAMIDINE AT ATOMIC RESOLUTION
1SBWA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF MUNG BEAN INHIBITOR LYSINE ACTIVE FRAGMENT COMPLEX WITH BOVINE BETA-TRYPSIN AT 1.8A RESOLUTION
1SFIA:16-27,A:121-232; A:28-120,A:233-245HIGH RESOLUTION STRUCTURE OF A POTENT, CYCLIC PROTEASE INHIBITOR FROM SUNFLOWER SEEDS
1T7CA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232CRYSTAL STRUCTURE OF THE P1 GLU BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1T8LA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232CRYSTAL STRUCTURE OF THE P1 MET BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1T8MA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232CRYSTAL STRUCTURE OF THE P1 HIS BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1T8NA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232CRYSTAL STRUCTURE OF THE P1 THR BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1T8OA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232CRYSTAL STRUCTURE OF THE P1 TRP BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1TAWA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN COMPLEXED TO APPI
1TBQH:28-120,H:233-247; K:28-120,K:233-247; H:16-27,H:121-232; K:16-27,K:121-232CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN
1TBRH:28-120,H:233-247; K:28-120,K:233-247; H:16-27,H:121-232; K:16-27,K:121-232CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN
1TGBA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF BOVINE TRYPSINOGEN AT 1.8 ANGSTROMS RESOLUTION. II. CRYSTALLOGRAPHIC REFINEMENT, REFINED CRYSTAL STRUCTURE AND COMPARISON WITH BOVINE TRYPSIN
1TGCA:16-27,A:121-232; A:28-120,A:233-245ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
1TGNA:17-27,A:121-232; A:28-120,A:233-245STRUCTURE OF BOVINE TRYPSINOGEN AT 1.9 ANGSTROMS RESOLUTION
1TGSZ:16-27,Z:121-232; Z:28-120,Z:233-245THREE-DIMENSIONAL STRUCTURE OF THE COMPLEX BETWEEN PANCREATIC SECRETORY INHIBITOR (KAZAL TYPE) AND TRYPSINOGEN AT 1.8 ANGSTROMS RESOLUTION. STRUCTURE SOLUTION, CRYSTALLOGRAPHIC REFINEMENT AND PRELIMINARY STRUCTURAL INTERPRETATION
1TIOA:16-27,A:121-232; A:28-120,A:233-245HIGH PACKING DENSITY FORM OF BOVINE BETA-TRYPSIN IN CYCLOHEXANE
1TLDA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF BOVINE BETA-TRYPSIN AT 1.5 ANGSTROMS RESOLUTION IN A CRYSTAL FORM WITH LOW MOLECULAR PACKING DENSITY. ACTIVE SITE GEOMETRY, ION PAIRS AND SOLVENT STRUCTURE
1TNGA:16-27,A:121-232; A:28-120,A:233-245PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNHA:16-27,A:121-232; A:28-120,A:233-245PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNIA:16-27,A:121-232; A:28-120,A:233-245PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNJA:16-27,A:121-232; A:28-120,A:233-245PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNKA:16-27,A:121-232; A:28-120,A:233-245PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNLA:16-27,A:121-232; A:28-120,A:233-245PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TOCB:28-120,B:233-247; D:28-120,D:233-247; F:28-120,F:233-247; H:28-120,H:233-247; B:16-27,B:121-232; D:16-27,D:121-232; F:16-27,F:121-232; H:16-27,H:121-232STRUCTURE OF SERINE PROTEINASE
1TPAE:16-27,E:121-232; E:28-120,E:233-245THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1TPOA:16-27,A:121-232; A:28-120,A:233-245THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1TPPA:16-27,A:121-232; A:28-120,A:233-245THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1TPSA:16-27,A:121-232; A:28-120,A:233-245ATOMIC STRUCTURE OF THE TRYPSIN-A90720A COMPLEX: A UNIFIED APPROACH TO STRUCTURE AND FUNCTION
1TX7A:16-27,A:121-232; A:28-120,A:233-244BOVINE TRYPSIN COMPLEXED WITH P-AMIDINOPHENYLMETHYLPHOSPHINIC ACID (AMPA)
1TX8A:16-27,A:121-232; A:28-120,A:233-244BOVINE TRYPSIN COMPLEXED WITH AMSO
1TYNA:16-27,A:121-232; A:28-120,A:233-245ATOMIC STRUCTURE OF THE TRYPSIN-CYCLOTHEONAMIDE A COMPLEX: LESSONS FOR THE DESIGN OF SERINE PROTEASE INHIBITORS
1UCYK:28-120,K:233-247; N:28-120,N:233-247; K:16-27,K:121-232; N:16-27,N:121-232; E:149B-247; H:16-149ATHROMBIN COMPLEXED WITH FIBRINOPEPTIDE A ALPHA (RESIDUES 7-19). THREE COMPLEXES, ONE WITH EPSILON-THROMBIN AND TWO WITH ALPHA-THROMBIN
1UVTH:28-120,H:233-241; H:16-27,H:121-232BOVINE THROMBIN--BM14.1248 COMPLEX
1UVUH:28-120,H:233-237; H:16-27,H:121-232BOVINE THROMBIN--BM12.1700 COMPLEX
1V2JT:16-27,T:121-232; T:28-120,T:233-245BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSRI) BT.C1
1V2KT:16-27,T:121-232; T:28-120,T:233-245FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(TRIPLE.GLU)BT.D2
1V2LT:16-27,T:121-232; T:28-120,T:233-245BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(TRIPLE.GLU)BT.D1
1V2MT:16-27,T:121-232; T:28-120,T:233-245BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(TRIPLE.GLU)BT.A1
1V2NT:16-27,T:121-232; T:28-120,T:233-245POTENT FACTOR XA INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(99/175/190)BT
1V2OT:16-27,T:121-232; T:28-120,T:233-245TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSYI)BT.B4
1V2PT:16-27,T:121-232; T:28-120,T:233-245TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSYI)BT.A4
1V2QT:16-27,T:121-232; T:28-120,T:233-245TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSWI)BT.B4
1V2RT:16-27,T:121-232; T:28-120,T:233-245TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSRI)BT.B4
1V2ST:16-27,T:121-232; T:28-120,T:233-245BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSFI.GLU)BT.D1
1V2TT:16-27,T:121-232; T:28-120,T:233-245TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSFI.GLU)BT.B4
1V2UT:16-27,T:121-232; T:28-120,T:233-245BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARINAT X(SSAI) BT.D1
1V2VT:16-27,T:121-232; T:28-120,T:233-245BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSAI) BT.C1
1V2WT:16-27,T:121-232; T:28-120,T:233-245TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSAI)BT.B4
1VGCC:151-245; B:16-146GAMMA-CHYMOTRYPSIN L-PARA-CHLORO-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
1VITH:28-120,H:233-247; H:16-27,H:121-232; G:149B-247; F:16-149ATHROMBIN:HIRUDIN 51-65 COMPLEX
1XUFA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN-BABIM-ZN+2, PH 8.2
1XUGA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN-BABIM-ZN+2, PH 8.2
1XUHA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN-KETO-BABIM-CO+2, PH 8.2
1XUIA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN-KETO-BABIM, ZN+2-FREE, PH 8.2
1XUJA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN-KETO-BABIM-ZN+2, PH 8.2
1XUKA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN-BABIM-SULFATE, PH 5.9
1Y3UA:16-27,A:121-232; A:28-120,A:233-244TRYPSIN INHIBITOR COMPLEX
1Y3VA:16-27,A:121-232; A:28-120,A:233-244TRYPSIN INHIBITOR COMPLEX
1Y3WA:16-27,A:121-232; A:28-120,A:233-244TRYPSIN INHIBITOR COMPLEX
1Y3XA:16-27,A:121-232; A:28-120,A:233-244TRYPSIN INHIBITOR COMPLEX
1Y3YA:16-27,A:121-232; A:28-120,A:233-244TRYPSIN INHIBITOR COMPLEX
1YCPH:28-120,H:233-242; H:16-27,H:121-232; M:150-243; K:16-146THE CRYSTAL STRUCTURE OF FIBRINOGEN-AA PEPTIDE 1-23 (F8Y) BOUND TO BOVINE THROMBIN EXPLAINS WHY THE MUTATION OF PHE-8 TO TYROSINE STRONGLY INHIBITS NORMAL CLEAVAGE AT ARGININE-16
1YP9A:253-27,A:121-232; A:28-120,A:233-244TRYPSIN INHIBITOR COMPLEX
1YPHE:149-245; F:149-245; C:16-146; D:16-146HIGH RESOLUTION STRUCTURE OF BOVINE ALPHA-CHYMOTRYPSIN
1YYY1:16-27,1:121-232; 1:28-120,1:233-245TRYPSIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1ZR0A:16-27,A:121-232; C:16-27,C:121-232; A:28-120,A:233-245; C:28-120,C:233-245CRYSTAL STRUCTURE OF KUNITZ DOMAIN 1 OF TISSUE FACTOR PATHWAY INHIBITOR-2 WITH BOVINE TRYPSIN
1ZZZA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
2A1DB:28-120,B:233-247; F:28-120,F:233-247; B:16-27,B:121-232; F:16-27,F:121-232STAPHYLOCOAGULASE BOUND TO BOVINE THROMBIN
2A7HA:7-18,A:109-216; A:19-108,A:217-228ON THE ROUTINE USE OF SOFT X-RAYS IN MACROMOLECULAR CRYSTALLOGRAPHY, PART III- THE OPTIMAL DATA COLLECTION WAVELENGTH
2AGEX:16-27,X:121-232; X:28-120,X:233-244SUCCINYL-AAPR-TRYPSIN ACYL-ENZYME AT 1.15 A RESOLUTION
2AGGX:16-27,X:121-232; X:28-120,X:233-244SUCCINYL-AAPK-TRYPSIN ACYL-ENZYME AT 1.28 A RESOLUTION
2AGIX:16-27,X:121-232; X:28-120,X:233-244THE LEUPEPTIN-TRYPSIN COVALENT COMPLEX AT 1.14 A RESOLUTION
2AH4X:16-27,X:121-232; X:28-120,X:233-244GUANIDINOBENZOYL-TRYPSIN ACYL-ENZYME AT 1.13 A RESOLUTION
2AYWA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN TRYPSIN AND A DESIGNED SYNTHETIC HIGHLY POTENT INHIBITOR IN THE PRESENCE OF BENZAMIDINE AT 0.97 A RESOLUTION
2BTCE:16-27,E:121-232; E:28-120,E:233-245BOVINE TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA PEPO TRYPSIN INHIBITOR II)
2BZAA:16-27,A:121-232; A:28-120,A:233-245BOVINE PANCREAS BETA-TRYPSIN IN COMPLEX WITH BENZYLAMINE
2CGAA:28-120,A:233-245; B:28-120,B:233-245; A:16-27,A:121-232; B:16-27,B:121-232BOVINE CHYMOTRYPSINOGEN A. X-RAY CRYSTAL STRUCTURE ANALYSIS AND REFINEMENT OF A NEW CRYSTAL FORM AT 1.8 ANGSTROMS RESOLUTION
2CHAC:149-245; G:149-245; B:16-146; F:16-146THE STRUCTURE OF CRYSTALLINE ALPHA-CHYMOTRYPSIN, $V.THE ATOMIC STRUCTURE OF TOSYL-ALPHA-CHYMOTRYPSIN AT 2 ANGSTROMS RESOLUTION
2D8WA:7-18,A:109-216; A:19-108,A:217-228STRUCTURE OF HYPER-VIL-TRYPSIN
2F3CE:16-27,E:118-225; E:28-117,E:226-237CRYSTAL STRUCTURE OF INFESTIN 1, A KAZAL-TYPE SERINEPROTEASE INHIBITOR, IN COMPLEX WITH TRYPSIN
2FI3E:16-27,E:121-232; E:28-120,E:233-244CRYSTAL STRUCTURE OF A BPTI VARIANT (CYS14->SER, CYS38->SER) IN COMPLEX WITH TRYPSIN
2FI4E:16-27,E:121-232; E:28-120,E:233-244CRYSTAL STRUCTURE OF A BPTI VARIANT (CYS14->SER) IN COMPLEX WITH TRYPSIN
2FI5E:16-27,E:121-232; E:28-120,E:233-244CRYSTAL STRUCTURE OF A BPTI VARIANT (CYS38->SER) IN COMPLEX WITH TRYPSIN
2FTLE:16-27,E:121-232; E:28-120,E:233-244CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH BPTI AT 100K
2FTMA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH THE BPTI VARIANT (TYR35->GLY)
2FX4A:16-27,A:121-232; A:28-120,A:233-244BOVINE TRYPSIN BOUND BY 4-PIPERIDINEBUTYRATE TO MAKE ACYLENZYME COMPLEX
2FX6A:16-27,A:121-232; A:28-120,A:233-244BOVINE TRYPSIN COMPLEXED WITH 2-AMINOBENZAMIDAZOLE
2G55A:7-18,A:109-216; A:19-108,A:217-228ANOMALOUS SUBSTRUCTURE OF TRYPSIN (P3121)
2G5NA:7-18,A:109-216; A:19-108,A:217-228INDOLE-AMIDINE COMPLEXES WITH BOVINE TRYPSIN
2G5VA:7-18,A:109-216; A:19-108,A:217-228INDOLE-AMIDINE COMPLEXES WITH BOVINE TRYPSIN
2G81E:16-27,E:121-232; E:28-120,E:233-244CRYSTAL STRUCTURE OF THE BOWMAN-BIRK INHIBITOR FROM VIGNA UNGUICULATA SEEDS IN COMPLEX WITH BETA-TRYPSIN AT 1.55 ANGSTRONS RESOLUTION
2G8TA:7-18,A:109-216; A:19-108,A:217-228INDOLE-AMIDINE COMPLEXES WITH BOVINE TRYPSIN
2GCHG:151-245; F:16-146REFINED CRYSTAL STRUCTURE OF GAMMA-CHYMOTRYPSIN AT 1.9 ANGSTROMS RESOLUTION
2GMTC:151-245; B:16-146THREE-DIMENSIONAL STRUCTURE OF CHYMOTRYPSIN INACTIVATED WITH (2S) N-ACETYL-L-ALANYL-L-PHENYLALANYL-CHLOROETHYL KETONE: IMPLICATIONS FOR THE MECHANISM OF INACTIVATION OF SERINE PROTEASES BY CHLOROKETONES
2ILNA:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-244; B:28-120,B:233-244CRYSTAL STRUCTURE OF THE BOWMAN-BIRK INHIBITOR FROM SNAIL MEDIC SEEDS IN COMPLEX WITH BOVINE TRYPSIN
2O9QA:19-30,A:121-228; A:31-120,A:229-241THE CRYSTAL STRUCTURE OF BOVINE TRYPSIN COMPLEXED WITH A SMALL INHIBITION PEPTIDE ORB2K
2ODYB:28-120,B:233-243; D:28-120,D:233-243; B:16-27,B:121-232; D:16-27,D:121-232THROMBIN-BOUND BOOPHILIN DISPLAYS A FUNCTIONAL AND ACCESSIBLE REACTIVE-SITE LOOP
2OTVA:16-27,A:121-238; A:28-120,A:239-250CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE TRYPSIN AND NICOTINAMIDE AT 1.56 A RESOLUTION
2OXSA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF THE TRYPSIN COMPLEX WITH BENZAMIDINE AT HIGH TEMPERATURE (35 C)
2P8OC:151-245; B:16-146CRYSTAL STRUCTURE OF A BENZOHYDROXAMIC ACID/VANADATE COMPLEX BOUND TO CHYMOTRYPSIN A
2PLXA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN COMPLEXED TO A SYNTHETIC PEPTIDE FROM VERONICA HEDERIFOLIA
2PTCE:16-27,E:121-232; E:28-120,E:233-245THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
2PTNA:16-27,A:121-232; A:28-120,A:233-245ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2TGAA:16-27,A:121-232; A:28-120,A:233-245ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2TGDA:17-27,A:121-232; A:28-120,A:233-245LACK OF THE TRANSITION STATE STABILIZATION SITE IS A FACTOR IN THE INACTIVITY OF TRYPSINOGEN, A SERINE PROTEASE ZYMOGEN. STRUCTURE OF DFP INHIBITED BOVINE TRYPSINOGEN AT 2.1 ANGSTROMS RESOLUTION
2TGPZ:16-27,Z:121-232; Z:28-120,Z:233-245THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
2TIOA:16-27,A:121-232; A:28-120,A:233-245LOW PACKING DENSITY FORM OF BOVINE BETA-TRYPSIN IN CYCLOHEXANE
2VGCC:151-245; B:16-146GAMMA-CHYMOTRYPSIN D-PARA-CHLORO-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
3BTDE:16-27,E:121-232; E:28-120,E:233-244THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN THE BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI.
3BTEE:16-27,E:121-232; E:28-120,E:233-243THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI.
3BTFE:16-27,E:121-232; E:28-120,E:233-245THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI.
3BTGE:16-27,E:121-232; E:28-120,E:233-244THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTHE:16-27,E:121-232; E:28-120,E:233-242THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTKE:16-27,E:121-232; E:28-120,E:233-243THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTME:16-27,E:121-232; E:28-120,E:233-244THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTQE:16-27,E:121-232; E:28-120,E:233-244THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTTE:16-27,E:121-232; E:28-120,E:233-244THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTWE:16-27,E:121-232; E:28-120,E:233-243THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3GCTG:151-245; F:16-146STRUCTURE OF GAMMA-*CHYMOTRYPSIN IN THE RANGE $P*H 2.0 TO $P*H 10.5 SUGGESTS THAT GAMMA-CHYMOTRYPSIN IS A COVALENT ACYL-ENZYME ADDUCT AT LOW $P*H
3PTBA:16-27,A:121-232; A:28-120,A:233-245THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
3PTNA:16-27,A:121-232; A:28-120,A:233-245ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
3TPIZ:16-27,Z:121-232; Z:28-120,Z:233-245THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
3VGCC:151-245; B:16-146GAMMA-CHYMOTRYPSIN L-NAPHTHYL-1-ACETAMIDO BORONIC ACID ACID INHIBITOR COMPLEX
4CHAC:149-245; G:149-245; B:16-146; F:16-146STRUCTURE OF ALPHA-*CHYMOTRYPSIN REFINED AT 1.68 ANGSTROMS RESOLUTION
4GCHG:151-245; F:16-146STRUCTURE AND ACTIVITY OF TWO PHOTOREVERSIBLE CINNAMATES BOUND TO CHYMOTRYPSIN
4TPIZ:16-27,Z:121-232; Z:28-120,Z:233-245THE REFINED 2.2-ANGSTROMS (0.22-NM) X-RAY CRYSTAL STRUCTURE OF THE TERNARY COMPLEX FORMED BY BOVINE TRYPSINOGEN, VALINE-VALINE AND THE ARG15 ANALOGUE OF BOVINE PANCREATIC TRYPSIN INHIBITOR
4VGCC:151-245; B:16-146GAMMA-CHYMOTRYPSIN D-NAPHTHYL-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
5CHAC:149-245; G:149-245; B:16-146; F:16-146THE REFINEMENT AND THE STRUCTURE OF THE DIMER OF ALPHA-*CHYMOTRYPSIN AT 1.67-*ANGSTROMS RESOLUTION
5GCHG:151-245; F:16-146CHEMISTRY OF CAGED ENZYMES /II$. PHOTOACTIVATION OF INHIBITED CHYMOTRYPSIN
5PTPA:16-27,A:121-232; A:28-120,A:233-244STRUCTURE OF HYDROLASE (SERINE PROTEINASE)
6CHAC:149-245; G:149-245; B:16-146; F:16-146STRUCTURE OF A TETRAHEDRAL TRANSITION STATE COMPLEX OF ALPHA-*CHYMOTRYPSIN AT 1.8-*ANGSTROMS RESOLUTION
6GCHG:151-245; F:16-146STRUCTURE OF CHYMOTRYPSIN-*TRIFLUOROMETHYL KETONE INHIBITOR COMPLEXES. COMPARISON OF SLOWLY AND RAPIDLY EQUILIBRATING INHIBITORS
7GCHG:151-245; F:16-146STRUCTURE OF CHYMOTRYPSIN-*TRIFLUOROMETHYL KETONE INHIBITOR COMPLEXES. COMPARISON OF SLOWLY AND RAPIDLY EQUILIBRATING INHIBITORS
8GCHG:150-245; F:16-146GAMMA-CHYMOTRYPSIN IS A COMPLEX OF ALPHA-CHYMOTRYPSIN WITH ITS OWN AUTOLYSIS PRODUCTS